ArticleGenes to cells : devoted to molecular & cellular mechanisms2021
Meflin defines mesenchymal stem cells and/or their early progenitors with multilineage differentiation capacity.
Article in Genes to cells : devoted to molecular & cellular mechanisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Unlocking the Cardioprotective Action of Human Amniotic Mesenchymal Stem Cells: A Review of the Current Documents.Health science reports · 2026Article
- Increased Meflin Expression in Cancer-Associated Fibroblasts Restrains Tumor Cell Proliferation and Shapes Vessel-Rich Stroma in Triple-Negative Breast Cancer.The American journal of pathology · 2026Article
- Cancer-Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Meflin/ISLR is a meningeal cell-specific marker involved in the development of meninges and meningioma progression.Brain pathology (Zurich, Switzerland) · 2026Article
- Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma.Oncogene · 2025Article
- Meflin/Islr is a marker of fibroblasts that arise in fibrotic regions after spinal cord injury.Nagoya journal of medical science · 2025Article
- Aging and cell expansion enhance microRNA diversity in small extracellular vesicles produced from human adipose-derived stem cells.Cytotechnology · 2025Article
- Light and scanning electron microscope characterization of mandibular symphysis tissue as a functional adaptation in the mandible development of human fetuses.Journal of anatomy · 2025Article
- Superoxide dismutase 2 deficiency in mesenchymal stromal cells induces sympathetic denervation and functional impairment of brown adipose tissue.Pathology international · 2025Article
- Structurally and mechanically tuned macroporous hydrogels for scalable mesenchymal stem cell-extracellular matrix spheroid production.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade.British journal of cancer · 2024Article
- NADPH oxidase 4 is dispensable for skin myofibroblast differentiation and wound healing.Redox biology · 2023Article
- Adipokines at the crossroads of obesity and mesenchymal stem cell therapy.Experimental & molecular medicine · 2023Review
- Possible disease-protective roles of fibroblasts in cancer and fibrosis and their therapeutic application.Nagoya journal of medical science · 2022Review
- Good and Bad Stroma in Pancreatic Cancer: Relevance of Functional States of Cancer-Associated Fibroblasts.Cancers · 2022Review
- Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.Life science alliance · 2022Article
- Article
- Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer.Pathology international · 2022Article
- Meflin defines mesenchymal stem cells and/or their early progenitors with multilineage differentiation capacity.Genes to cells : devoted to molecular & cellular mechanisms · 2021Article
- Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Mesenchymal stem cells (MSCs) are the likely precursors of multiple lines of mesenchymal cells. The existence of bona fide MSCs with self-renewal capacity and differentiation potential into all mesenchymal lineages, however, has been unclear because of the lack of MSC-specific marker(s) that are not expressed by the terminally differentiated progeny. Meflin, a glycosylphosphatidylinositol-anchored protein, is an MSC marker candidate that is specifically expressed in rare stromal cells in all tissues. Our previous report showed that Meflin expression becomes down-regulated in bone marrow-derived MSCs cultured on plastic, making it difficult to examine the self-renewal and differentiation of Meflin-positive cells at the single-cell level. Here, we traced the lineage of Meflin-positive cells in postnatal and adult mice, showing that those cells differentiated into white and brown adipocytes, osteocytes, chondrocytes and skeletal myocytes. Interestingly, cells derived from Meflin-positive cells formed clusters of differentiated cells, implying the in situ proliferation of Meflin-positive cells or their lineage-committed progenitors. These results, taken together with previous findings that Meflin expression in cultured MSCs was lost upon their multilineage differentiation, suggest that Meflin is a useful potential marker to localize MSCs and/or their immature progenitors in multiple tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.